Lake Street Initiates Coverage On Quoin Pharmaceuticals with Buy Rating, Announces Price Target of $20

Lake Street analyst Thomas Flaten has initiated coverage on Quoin Pharmaceuticals (NASDAQ: QNRX) with a Buy rating. The analyst has set a price target of $20 for the stock.